In 2022, reflex testing for an ALK rearrangement in all newly diagnosed advanced NSCLC adenocarcinomas, not otherwise specified histology, or non-smoking squamous cancers, is the gold standard. This evidence concerns the gene ALK and adenocarcinoma.